Drug Type Oligonucleotide |
Synonyms- |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), IL-13Rα2 inhibitors(Interleukin-13 receptor subunit alpha-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Preclinical | US | 17 Apr 2023 |